Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 62022TA0037

    Case T-37/22: Judgment of the General Court of 1 March 2023 — Romedor Pharma v EUIPO — Perfect Care Distribution (Cerviron) (EU trade mark — Invalidity proceedings — EU word mark Cerviron — Non-registered earlier national trade mark CERVIRON — Relative ground for invalidity — Article 8(4) and Article 60(1)(c) of Regulation (EU) 2017/1001)

    OJ C 134, 17.4.2023, p. 12–13 (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    17.4.2023   

    EN

    Official Journal of the European Union

    C 134/12


    Judgment of the General Court of 1 March 2023 — Romedor Pharma v EUIPO — Perfect Care Distribution (Cerviron)

    (Case T-37/22) (1)

    (EU trade mark - Invalidity proceedings - EU word mark Cerviron - Non-registered earlier national trade mark CERVIRON - Relative ground for invalidity - Article 8(4) and Article 60(1)(c) of Regulation (EU) 2017/1001)

    (2023/C 134/16)

    Language of the case: Romanian

    Parties

    Applicant: Romedor Pharma SRL (Focşani, Romania) (represented by: E.-M. Dicu, lawyer)

    Defendant: European Union Intellectual Property Office (represented by: R. Manea and E. Markakis, acting as Agents)

    Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Perfect Care Distribution SRL (Bucharest, Romania) (represented by: R. Pop, lawyer)

    Re:

    By its action under Article 263 TFEU, the applicant seeks annulment of the decision of the Second Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 17 November 2021 (Case R 520/2021-2).

    Operative part of the judgment

    The Court:

    1.

    Dismisses the action;

    2.

    Orders Romedor Pharma SRL to bear its own costs and to pay those incurred by the European Union Intellectual Property Office (EUIPO);

    3.

    Orders Perfect Care Distribution SRL to bear its own costs.


    (1)  OJ C 138, 28.3.2022.


    Top